Huibo Zhou

o Business Achievements: FY 2022 Crestor 390M💲≤, Brilinta 119M💲; Crestor GR +19% (Institutional +16%, Outpatient +23%), Brilinta MS 23%; o Responsible for VBP products Crestor (lipid-lowering drug, rosuvastatin) and Brilinta (antiplatelet drug, ticagrelor), led the team to win the "VBP Product Peak CEO Award" and the "Digital Collaboration CEO Award" once. Collaborated with Key Accounts, Commercial , Retail, Medical, and Sales to drive hospital business growth, maximizing the Out-of-Hospital.  Category expansion: Accelerated VBP task completion by expanding market share of molecular formula categories, assisting in managing VBP task pressure. Utilized the Chest Pain Center platform to bridge BU and grassroots hospitals, accelerating concept penetration.  Innovative strategic partnerships: Collaborated with Key Accounts to assist in precise VBP task management, combined with projects like "Chest Pain Center" and "One Pack of Medication" to improve product listing retention and sales volume retention.  External adoption extension: Strengthened policy implementation in key hospitals and retail pharmacies, using models like "Regular Purchase" and "Diagnosis and Treatment Service Package" to enhance external adoption. Enhanced brand exposure in retail and e-commerce channels, prolonging DOT. o In Q4 2022, took on the additional role of Forxiga Cardiovascular Area, mobilized cross-department efforts to establish a "Dual Engine" brand strategy. Quickly achieved an 80% patient share for Forxiga in heart failure treatment and expanded it to a broader population using "Heart Failure Centers" and "Chest Pain Centers" by quality control anchors.

o Business Achievements: FY 2019 Xarelto 2.6 billion RMB, GR +186%, cardiovascular contribution 55%, the largest anticoagulant drug in China; FY 2020 Aspirin 1.4 billion RMB, GR +14%, MS 95%, the most widely used antiplatelet drug in China. o 2015-2019: Successfully launched the oral anticoagulant Xarelto in the cardiovascular field. Led the creation of the "Atrial Fibrillation Center" project in 2016, expanding the systemization of anticoagulation concepts, covering 3000+ hospitals, and increasing product listing. Initiated the establishment of "Atrial Fibrillation Day" starting from 2017. In November 2019, collaborated with Ge Junbo, Huo Yong, Huang Congxin, and others to create a Guinness World Record achieved by 599 cardiovascular doctors, promoting the penetration of anticoagulation concepts to grassroots levels. o 2019-2020: Responsible for BayAspirin and Adalat, drove the release of the primary prevention guidelines for cardiovascular disease, clearly recommending the advantages of aspirin. Leveraged the "Chest Pain Center" to strengthen expert collaborations and seize VBP opportunities, successfully gaining market share.

Product manager of Xarelto VTEp(VTE prevention in patients received THR & TKR, the only launched indication that time) indication in Central Marketing Task and responsibility 1. Develop and implement brand strategy and plan for Xarelto VTEp indication, finalize the key differentiate message of Xarelto to beat main competitor Apixaban. Ensure proper implementation by sales and regional marketing colleagues and high sales performance of Xarelto; 2. Develop and maintain close relationships with national level key opinion leaders in Orthopedic department, come up VTE prevention consensus for patients suffered trauma in 2012, VTE screening consensus for patients suffered trauma in 2013 ; 3. Design and prepare all national level promotional campaigns and materials, organize 5th launch year campaign which include 5 national level scientific congresses, 5 creative promotion tools, 5 year case collection, 5 year photograph sharing. Start Thrombosis Management Ward project to increase the disease awareness in Wound Orthopedics; 4. Design and carry out marketing research with marketing access colleagues; 5. Collaborate with sales training department and develop core training information.

From Mar 2010 to 2012 Feb MSL and Medical advisor of Xarelto in Medical department Task and responsibility 1. Develop and implement medical strategy and plan for Xarelto Venous indications(both VTE prevention in OS and VTE treatment in vascular surgeon department), such as bleeding risk management strategy for patients receiving anticoagulant; 2. Collect and manage scientific and study concept from top key opinion leaders, work closely with KOLs to initiate the first clinical guideline which including Xarelto as DVT treatment choice; 3. Support marketing and sales colleagues with scientific support in national and regional level events; 4. Develop and deliver scientific information to MSLs; 5. Collaborate with sales training department and develop scientific contents;